Literature DB >> 33934430

Correction.

.   

Abstract

Year:  2021        PMID： 33934430      PMCID： PMC8088966          DOI： 10.1111/cas.14893

Source DB:  PubMed          Journal:  Cancer Sci        ISSN： 1347-9032            Impact factor:   6.716


× No keyword cloud information.
  1 in total

1.  Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.

Authors:  Di Bei; Mayu Osawa; Shinji Uemura; Tomoya Ohno; Jogarao Gobburu; Amit Roy; Mayumi Hasegawa
Journal:  Cancer Sci       Date:  2020-01-21       Impact factor: 6.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.